Given that several p53‐activating compounds are currently under clinical trials for the treatment of cancers carrying wild‐type p53,[47, 48] our findings of the inhibitory effect of MLF2 on p53 function therefore suggest MLF2 as a potential therapeutic target for cancer. This evidence concerns the gene TP53 and cancer.